[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100483654":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":11,"locations":23,"responsibleParty":42,"collaborators":11,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":11,"enrollmentInfo":56,"targetDuration":11,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":11,"overallStatus":25,"whyStopped":11,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Seoul National University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ramosetron","EXPERIMENTAL",null,[13],"Drug: Ramosetron",{"label":15,"type":16,"description":11,"interventionNames":17},"Loperamide","ACTIVE_COMPARATOR",[13],[19],{"type":20,"name":9,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","Ramosetron, 4 weeks",[15,9],[24],{"facility":5,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":11,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"RECRUITING","Seoul","Jongro-gu","03080","South Korea",{"type":31,"coordinates":32},"Point",[33,34],126.9784,37.566,{"lat":34,"lon":33},[37],{"name":38,"role":39,"phone":40,"phoneExt":11,"email":41},"Seung-Bum Ryoo, MD, PhD","CONTACT","+82-2-2072-7294","sbryoomd@gmail.com",{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Ryoo, Seung-Bum","Clinical Associate Professor","100483654","5-ht3-receptor-antagonist-ramosetron-vs-loperamide-for-the-treatment-of-low-anterior-resection-syndromeralars-100483654",false,"NCT05577845","5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS)","Safety & Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) Versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial","RaLARS","Inclusion Criteria:\n\n* mid and low rectal cancer (AV\\\u003C15cm)\n* stage II, III, preop long-course CCRT, then ileostomy repair\n* about 1\\~12 months after operation (no stomy)\n* about 1\\~6 months after ileostomy repair\n* major LARS\n\nExclusion Criteria:\n\n* recurred rectal cancer\n* stage IV\n* IBD\n* uncontrolled preoperative fecal incontinence or constipation","ALL","19 Years",{"count":57,"type":58},212,"ESTIMATED","INTERVENTIONAL",[61],"NA","Safety \\& Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial",[64],"LARS - Low Anterior Resection Syndrome","2023-04-24",{"date":67,"type":68},"2023-04-25","ACTUAL",{"date":70,"type":68},"2023-03-27",{"date":72,"type":58},"2032-12",{"name":5,"class":6},1]